References

Acute Oncology Guidelines
NHS Lothian

Information in this section of the RightDecisions app has been taken from the corresponding antithrombotic guidelines in OOQS. These guidelines are fully referenced within the text and are available to view on the NHS Lothian intranet, should there be any queries.

As this document and associated references are regularly updated. Please see the most updated document on OOQS to view references cited within the text.

 

References

  1. Carrier, M., et al., Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med, 2019. 380(8): p. 711-719.
  2. Shinagare, A.B., et al., Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer, 2011. 117(16): p. 3860-6.
  3. Watson, H.G., et al., Guideline on aspects of cancer-related venous thrombosis. Br J Haematol, 2015. 170(5): p. 640-8.
  4. Kahn, S.R., et al., Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet, 2014. 383(9920): p. 880-8.
  5. Key, N.S., et al., Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 2020. 38(5): p. 496-520.
  6. Alikhan, R., et al., Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline. British Journal of Haematology, 2024. 205(1): p. 71-87.
  7. Khorana, A.A., et al., Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 2008. 111(10): p. 4902-7.
  8. Apixaban SPC. [cited 2018 7/8/2018]; Available from: https://www.medicines.org.uk/emc/product/2878/smpc.
  9. Khorana, A.A., et al., Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer, 2007. 110(10): p. 2339-46.
  10. Agnelli, G., et al., Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med, 2020. 382(17): p. 1599-1607.
  11. Ageno, W., et al., Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thromb Haemost, 2021. 121(5): p. 616-624.
  12. McBane, R.D., 2nd, et al., Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost, 2020. 18(2): p. 411-421.
  13. Raskob, G.E., et al., Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med, 2018. 378(7): p. 615-624.
  14. Mulder, F.I., et al., Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research, 2018. 164: p. S194.
  15. Young, A.M., et al., Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol, 2018. 36(20): p. 2017-2023.
  16. Trujillo-Santos J, et al; RIETE Investigators. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study. Res Pract Thromb Haemost. 2022 Jun 3;6(4)..
  17. Hull, R.D., et al., Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med, 2006. 119(12): p. 1062-72.
  18. Palla, A., et al., Is incidentally detected pulmonary embolism in cancer patients less severe? A case-control study. Cancer Invest, 2012. 30(2): p. 131-4.
  19. den Exter, P.L., et al., Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol, 2011. 29(17): p. 2405-9.
  20. Menapace, L.A., et al., Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost, 2011. 106(2): p. 371-8.
  21. O'Connell, C., et al., Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost, 2011. 9(2): p. 305-11.
  22. McBane, R.D., 2nd, et al., Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. Eur J Haematol, 2020. 104(2): p. 88-96.
  23. Kitchen, S., et al., Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol, 2014. 166(6): p. 830-41.
  24. Enoxaparin (Inhixa) Summary of Product Characteristics. Accessed at www.medicines.org.uk on 18/09/25
  25. Watson, H., S. Davidson, and D. Keeling, Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol, 2012. 159(5): p. 528-40.
  26. Farge, D., et al., International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol, 2016. 17(10): p. e452-e466.
  27. NCCN Guidelines for Venous Thromboembolic Disease. 2018 [cited 2018 1/8/2018]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.
  28. Ranjan, S., et al., Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer, 2024. 130(9): p. 1577-1589.
  29. Zwicker, J.I., R. Karp Leaf, and M. Carrier, A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost, 2016. 14(9): p. 1736-40.
  30. Hunter, B.D., T. Minichiello, and S. Bent, Anticoagulation for the treatment of venous thromboembolism in patients with brain metastases: a meta-analysis and systematic review. J Thromb Thrombolysis, 2017. 44(3): p. 392-398.
  31. Donato, J., et al., Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood, 2015. 126(4): p. 494-9.
  32. Alvarado, G., et al., Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res, 2012. 22(4): p. 310-5.
  33. Jo, J., et al., Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. Neuro-Oncology, 2023. 25(8): p. 1381-1394.
  34. EASL. EASL Clinical Practice Guidelines: Vascular diseases of the liver. 2015 24/9/18]; Available from: http://www.easl.eu/medias/cpg/Vascular-liver-diseases/English-report.pdf.
  35. Kreuziger, L.B., W. Ageno, and A. Lee, Management of incidental splanchnic vein thrombosis in cancer patients. Hematology Am Soc Hematol Educ Program, 2014. 2014(1): p. 318-20.
  36. Tufano, A., et al., Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Thromb Res, 2018. 164: p. 69-74.
  37. Amitrano, L., et al., Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol, 2007. 102(11): p. 2464-70.
  38. Connolly, G.C., et al., Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res, 2008. 122(3): p. 299-306.
  39. Scott, G., A.J. Mahdi, and R. Alikhan, Superficial vein thrombosis: a current approach to management. Br J Haematol, 2015. 168(5): p. 639-45.
  40. Edoxaban SPC. [cited 2018 7/8/18]; Available from: https://www.medicines.org.uk/emc/product/6907/smpc.
  41. Rivaroxaban SPC. [cited 2018 7/8/18]; Available from: https://www.medicines.org.uk/emc/product/2793/smpc.

Editorial Information

Next review date: 01/11/2024